Cargando…

A metabolic vulnerability of small-cell lung cancer

Detalles Bibliográficos
Autores principales:	Nomura, Miyuki, Morita, Mami, Tanuma, Nobuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122350/ https://www.ncbi.nlm.nih.gov/pubmed/30190785 http://dx.doi.org/10.18632/oncotarget.25964

Ejemplares similares

Revisiting glucose metabolism in cancer: lessons from a PKM knock-in model
por: Sato, Taku, et al.
Publicado: (2018)

Dietary intervention as a therapeutic for cancer
por: Morita, Mami, et al.
Publicado: (2020)

Metabolic Reprogramming and Vulnerabilities in Cancer
por: Lyssiotis, Costas A., et al.
Publicado: (2019)

Metabolic vulnerabilities of MYC-induced cancer
por: Gouw, Arvin M., et al.
Publicado: (2016)

Lipid Metabolism as a Targetable Metabolic Vulnerability in Colorectal Cancer
por: Zaytseva, Yekaterina
Publicado: (2021)

Functions of metabolic enzymes in the development of non‐small cell lung cancer
por: Zhao, Gang
Publicado: (2019)

Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer
por: Seguin, Laetitia, et al.
Publicado: (2018)

Targeting the Metabolic Vulnerability of ARID1A-Deficient Hepatocellular Carcinoma
por: Chan, For-Fan, et al.
Publicado: (2022)

Surgery in limited-disease small-cell lung cancer
por: Koul, Parvaiz A.
Publicado: (2012)

Molecular basis of heterogeneity in small cell lung cancer
por: Tenjin, Yuki
Publicado: (2022)

Small Cell Lung Cancer: A New Era Is Beginning?
por: Morabito, Alessandro, et al.
Publicado: (2021)

The not so small role of adjuvant chemotherapy in resected non-small cell lung cancer
por: Almquist, Daniel R., et al.
Publicado: (2021)

Stereotactic Radiotherapy for Stage I Small Cell Lung Cancer
por: Verma, Vivek, et al.
Publicado: (2016)

Evolution in the management of non-small cell lung cancer in Brazil
por: Fernandes, Caio Júlio Cesar dos Santos
Publicado: (2017)

Realities of KRAS-mutated non-small cell lung cancer
por: Min, Young Joo
Publicado: (2017)

Immunotherapy in non-small cell lung cancer: advancements and challenges
por: Zhou, Fei, et al.
Publicado: (2021)

Resectable non-small cell lung cancer: an evolving landscape
por: Loh, Jerold, et al.
Publicado: (2022)

Immunotherapy as a targeted therapy in non-small cell lung cancer
por: Rocco, Danilo, et al.
Publicado: (2019)

Metabolic vulnerabilities of metastasizing cancer cells
por: Fendt, Sarah-Maria
Publicado: (2019)

Prenatal Air Pollution and Child Lung Function: The Impossible Search for a Vulnerable Trimester
por: Rice, Mary B., et al.
Publicado: (2020)

Histology Matters: Individualizing Treatment in Non-Small Cell Lung Cancer
por: Neal, Joel W.
Publicado: (2010)

Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer
por: Mamdani, Hirva, et al.
Publicado: (2017)

Immunotherapy in non‐small cell lung cancer: The past, the present, and the future
por: Lu, Meng, et al.
Publicado: (2019)

Biomarkers for Non-Small Cell Lung Cancer: From the Bench to the Bedside
por: de Mello, Ramon Andrade, et al.
Publicado: (2020)

Identifying successful biomarkers for patients with non-small-cell lung cancer
por: Friedlaender, Alex, et al.
Publicado: (2019)

Small-Cell Lung Cancer: Is the Black Box Finally Opening Up?
por: Hiddinga, Birgitta I., et al.
Publicado: (2021)

Treatment strategy of EGFR-mutated non-small cell lung cancer
por: Tanaka, Fumihiro, et al.
Publicado: (2022)

Surgery for Non-Small Cell Lung Cancer in the Personalized Therapy Era
por: Chiappetta, Marco, et al.
Publicado: (2023)

Neoadjuvant immunotherapy in resectable non-small cell lung cancer at a checkpoint
por: Faltermeier, Claire M., et al.
Publicado: (2021)

Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer
por: Young, Jonathan H., et al.
Publicado: (2016)

The vulnerability of RB loss in breast cancer: Targeting a void in cell cycle control
por: Knudsen, Erik S., et al.
Publicado: (2018)

Cell Metabolism Therapy by Small Natural Compounds
por: Nesci, Salvatore, et al.
Publicado: (2023)

Complex EGFR mutations in non-small cell lung cancer: a distinct entity?
por: Bieńkowski, Michał, et al.
Publicado: (2022)

New Insights into the Epigenomic Landscape of Small-Cell Lung Cancer: A Game Changer?
por: Sarode, Poonam, et al.
Publicado: (2022)

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer
por: Riess, Jonathan W., et al.
Publicado: (2016)

Biomarkers predictive value in early stage non-small cell lung cancer
por: Malapelle, Umberto, et al.
Publicado: (2020)

Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods
por: Zarogoulidis, Paul, et al.
Publicado: (2019)

Neoadjuvant immunotherapy for patients with non-small cell lung cancer—current evidence
por: Cao, Christopher, et al.
Publicado: (2020)

Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Critical points in the management of EGFR-mutated non-small cell lung cancer
por: Casaluce, Francesca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8nedqok68k3usfdkb7no630q9k